Ardent Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ardent Health (ARDT).

Price Target Range — 9 Quarters

Analyst Consensus — 13 Analysts

9Buy

3Hold

1Sell

Consensus RatingBuy# Analysts13Avg. Consensus PT$16Upside to Avg. PT+46.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	BMO Capital	Sean Dodge	Initiate	Market Perform	$11
Sep 18, 2026	Leerink Partners	Whit Mayo	Maintained	Outperform	$14
Aug 10, 2026	RBC Capital	Ben Hendrix	PT Raise	Outperform	$12→$13
Aug 6, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$12→$13
Aug 6, 2026	Guggenheim	Jason Cassorla	PT Raise	Buy	$13→$14
Jul 14, 2026	Truist Securities	David Macdonald	PT Cut	Buy	$13→$12
Jul 9, 2026	RBC Capital	Ben Hendrix	PT Cut	Outperform	$13→$12
May 7, 2026	UBS	A.J. Rice	PT Raise	Buy	$13→$14
Mar 10, 2026	RBC Capital	Ben Hendrix	PT Cut	Outperform	$14→$13
Mar 6, 2026	Leerink Partners	Whit Mayo	PT Cut	Outperform	$16→$15
Jan 20, 2026	JP Morgan	Benjamin Rossi	PT Cut	Neutral	$12→$11
Dec 18, 2025	UBS	A.J. Rice	PT Cut	Buy	$15→$14
Dec 18, 2025	Mizuho	Ann Hynes	PT Cut	Outperform	$20→$12
Nov 24, 2025	JP Morgan	Benjamin Rossi	PT Cut	Neutral	$15→$12
Nov 18, 2025	Mizuho	Ann Hynes	PT Cut	Outperform	$20→$13
Nov 18, 2025	Guggenheim	Jason Cassorla	PT Cut	Buy	$18→$15
Nov 17, 2025	Keybanc	Matthew Gillmor	Downgrade	Overweight→Sector Weight	—
Nov 14, 2025	RBC Capital	Ben Hendrix	PT Cut	Outperform	$21→$16
Nov 14, 2025	Truist Securities	David Macdonald	PT Cut	Buy	$21→$13
Nov 14, 2025	Stephens & Co.	Scott Fidel	PT Cut	Overweight	$21→$17

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Ardent Health with Market Perform Rating, Announces Price Target of $11

BMO Capital analyst Sean Dodge initiates coverage on Ardent Health (NYSE:ARDT) with a Market Perform rating and announces Price Target of $11.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13

RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and raises the price target from $12 to $13.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Ardent Health, Raises Price Target to $13

Truist Securities analyst David Macdonald maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $12 to $13.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Ardent Health, Raises Price Target to $14

Guggenheim analyst Jason Cassorla maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $13 to $14.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Ardent Health, Lowers Price Target to $12

Truist Securities analyst David Macdonald maintains Ardent Health (NYSE:ARDT) with a Buy and lowers the price target from $13 to $12.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Ardent Health, Lowers Price Target to $12

RBC Capital analyst Ben Hendrix maintains Ardent Health (NYSE:ARDT) with a Outperform and lowers the price target from $13 to $12.

Benzinga Newsdesk

Ardent Health Inc

Ardent Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Ardent Health with Market Perform Rating, Announces Price Target of $11

PRO
RBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13

PRO
Truist Securities Maintains Buy on Ardent Health, Raises Price Target to $13

PRO
Guggenheim Maintains Buy on Ardent Health, Raises Price Target to $14

PRO
Truist Securities Maintains Buy on Ardent Health, Lowers Price Target to $12

PRO
RBC Capital Maintains Outperform on Ardent Health, Lowers Price Target to $12

People Also Watch

People Also Watch

Ardent Health Inc

Ardent Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBMO Capital Initiates Coverage On Ardent Health with Market Perform Rating, Announces Price Target of $11

PRORBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13

PROTruist Securities Maintains Buy on Ardent Health, Raises Price Target to $13

PROGuggenheim Maintains Buy on Ardent Health, Raises Price Target to $14

PROTruist Securities Maintains Buy on Ardent Health, Lowers Price Target to $12

PRORBC Capital Maintains Outperform on Ardent Health, Lowers Price Target to $12

People Also Watch

People Also Watch

PRO
BMO Capital Initiates Coverage On Ardent Health with Market Perform Rating, Announces Price Target of $11

PRO
RBC Capital Maintains Outperform on Ardent Health, Raises Price Target to $13

PRO
Truist Securities Maintains Buy on Ardent Health, Raises Price Target to $13

PRO
Guggenheim Maintains Buy on Ardent Health, Raises Price Target to $14

PRO
Truist Securities Maintains Buy on Ardent Health, Lowers Price Target to $12

PRO
RBC Capital Maintains Outperform on Ardent Health, Lowers Price Target to $12